8-K:重大事件
10-Q:季度报表
8-K:Reviva公布2024年第一季度财务业绩和近期业务亮点
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:重大事件
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 10-K:年度报表
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:重大事件
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:重大事件
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | NT 10-K:其他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13D/A:超过5%持股股东披露文件(修正)-Laxminarayan Bhat(10.2%)
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13G/A:超过5%持股股东披露文件(修正)-TANG CAPITAL PARTNERS, LP(9.99%),TANG CAPITAL MANAGEMENT, LLC(9.99%)等
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13G:超过5%持股股东披露文件-Armistice Capital, LLC(6.32%),Steven Boyd(6.32%)
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | EFFECT:其他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 424B4:募资说明书
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | CORRESP:信函
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | UPLOAD:其他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | S-3:特定交易注册声明
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13D/A:超过5%持股股东披露文件(修正)-Parag Saxena(19.9%),Vedanta Partners, LLC(19.4%)等
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 4:持股变动声明-董事 SAXENA PARAG
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:重大事件
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 424B5:募资说明书
暂无数据